Gene Query: MB

Dataset Description Geneva Score
tRNA modification landscape selectively controls mitochondrial translation efficiency in MERRF 78.31
Transcriptome profiling of a mouse model of alveolar soft part sarcoma 60.11
EP400 is required for Max and MCPyV mediated gene activation 58.4
HuR controls apoptosis and activation response without effects on cytokine 3′ UTRs 51.75
Integrated Profiling of mRNAs and microRNAs to Identify Potential Biomarkers for Oral Malignant Transformation 39.05
Integrated Profiling of mRNAs and microRNAs to Identify Potential Biomarkers for Oral Malignant Transformation [mRNA-Seq] 39.05
Chemical Enhancement of Direct Cardiac Reprogramming In Vitro and In Vivo 37.3
Epigenomic landscape during organ formation in human early embryos 33.69
hiPSCs unravel aberrant TGFβ signaling as an etiology of left ventricular non-compaction 32.2
Gene expression changes associated with resistance to tagraxofusp (SL-401) 30.23
Transcriptome of human white and brown adipose tissue biopsies 29.24
circRNA profile in hypopharyngeal cancer 27.07
Gene expression profiling of iPSC-derived cardiomyocytes with BAG3 mutations 26.05
Gene expression profile in response to HIF-1α inhibition together with PPARα activation and the postnatal factors (T3, IGF-1 and dexamethasone) in hiPSC-CMs 24.36
Transcriptome-wide identification of CELF2 functional targets in T cells 23.66
Gene expression, methylome and splicing of THP-1 monocytic cells and THP-1-derived macrophage 23.0
Prolyl hydroxylation regulates protein degradation, synthesis, and splicing in human induced pluripotent stem cell-derived cardiomyocytes 19.15
Tyrosine Kinase Inhibitor Cardiotoxicity 18.24
High-Throughput Screening of Human Induced Pluripotent Stem Cell Cardiomyocytes Predicts Tyrosine Kinase Inhibitor Cardiotoxicity 18.24
Repurposing of promoters and enhancers during mammalian evolution 18.09
Dynamic reorganization of nuclear architecture during human cardiogenesis 17.86
Dynamic reorganization of nuclear architecture during human cardiogenesis [RNA-seq] 17.86
MicroRNA Marker Based Prognostication of Oral Squamous Cell Carcinoma 17.58
De novo reconstruction of human adipose reveals conserved lncRNAs as regulators of brown adipogenesis 17.37
AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition 17.32
Induction of Cardiomyocyte Proliferation [pz-822_human] 16.99
Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration 16.99
NR2F2 study 16.26
Estrogen response in breast cancer cell line MCF-7 is dependent on NR2F2 [RNA-seq] 16.26
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq) 16.16
GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance 15.46
Luminal lncRNAs Regulation by ERα-controlled Enhancers in a Ligand-independent Manner in Breast Cancer Cells 15.11
Single-cell RNA-seq reveals novel cell differentiation dynamics during human airway epithelium regeneration 15.01
Chronic cadmium exposure decreases the dependency of MCF7 breast cancer cells on ERα 14.76
Transcriptomes in healthy and CHB fetal hearts 13.72
Molecular mechanism underlying increased ischemic damage in the ALDH2*2 genetic polymorphism using a human iPSC model system 12.89
12.09
Transcriptomic analysis of the effect of trastuzumab in human iPSC-CMs 11.71
Transcriptome profiles of moderate dysplasia in oral mucosa associated with malignant conversion 10.9
Effects of Spaceflight on Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Structure and Function 10.85
Effects on gene expression of ibrutinib treatment in human stem cells-derived atrial- and ventricular-like cardiomyocytes 10.63
Genome-wide functional assessment of enhancer activities in the human genome 10.61
PR isoform-specific ER and PR chromatin binding and gene expression observed in-vitro in breast cancer cells. 10.07
Effect of CHKA knockdown on C4-2 cell transcriptome 9.98
RNA-seq differential expression studies: more sequence, or more replication? 9.77
Identifying a novel candidate diagnostic and prognostic biomarker SPRR3 for oral squamous cell carcinoma via mRNA Sequencing and Bioinformatics 9.73
The ribosomal prolyl-hydroxylase OGFOD1 decreases during cardiac differentiation, modulates translation and spliceosomal processes 9.51
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) 9.43
BET bromodomain inhibition 9.12
Effect of BET bromodomain inhibition with JQ1 in stressed human derived iPS cardiomyocytes 9.12
Profiling and bioinformatics analyses reveal differential expression of circular RNA in tongue cancer revealed by high-throughput sequencing 9.1
HNRNPM-regulated splicing dependencies in prostate cancer 8.81
HNRNPM-regulated splicing dependencies in prostate cancer [RNA-Seq] 8.81
lncRNA-PCAT1 knockdown effect on the gene expression of androgen independent LNCaP (LNCaP-AI) cell line 8.81
Transcriptional differences between skin from patients with atopic dermatitis and control skin obtained from the healthy margins of Mohs surgery patients 8.78
Expression profile of LNCaP/AR cells with or without HNF4G expression grown for long term in charcoal stripped-serum (CSS) media 8.73
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-Seq KO] 8.53
AR-independent prostate cancer is sustained through FGF signaling 8.51
Gene Expression of Breast Cancer Cell Lines Across Biomaterial Platforms 8.28
Expression profile of HNF1A knockdown and overexpression in 22RV1 and LNCaP cells respectively 8.17
RNA Seq analysis of NKX2-5 Null and Het human embryonic stem cells in cardiomyogenesis 7.96
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability 7.86
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (22RV1 RNA-seq) 7.86
yylncT acts as a gatekeeper of the mesodermal transcriptional program by local modulation of DNMT3B [human_2] 7.47
Role for citron kinase in prostate cancer growth 7.41
The transcriptome of Kawasaki Disease arteritis 7.37
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine resistant breast cancer 7.34
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [RNA-seq] 7.34
Determination of a comprehensive alternative splicing regulatory network and the combinatorial regulation by key factors during Epithelial-to-Mesenchymal Transition [ESRP KD] 7.19
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells 7.17
Arnica montana stimulates extracellular matrix gene expression in human macrophages differentiated to wound-healing phenotype. Tested on 5 concentrations. 6.96
The transcriptome and chromatin accessbility landscape of mammalian germline 6.86
CUREfast: Accelerating research with families 6.83
CDK4/6 inhibitor resistance in prostate cancer 6.65
BioProject PRJNA381064: Convergent origination of a Drosophila-like dosage compensation mechanism in a reptile lineage (Gene expression profiling in several tetrapod species, bulk tissue RNA-seq) 6.59
Differential expression in LNCaP cells expressing the wild-type androgen receptor (AR-WT) or the ligand-independent AR-V7 splice variant 6.58
mRNA differential expression in LNCaP cells expressing the wild-type androgen receptor (AR-WT) or the ligand-independent AR-V7 splice variant 6.58
Single-Cell reconstruction of differentiation trajectory reveals essential dynamics in human cardiac lineage commitment 6.43
Gene expression profiling of LNCaP cells following shRNA-mediated knockdown of TMEFF2 and growth in presence and absence of dihydrotestosterone 6.24
Transcriptional landscape of epithelial and immune cell populations revealed through FACS-seq of healthy human skin 6.13
siRNA-mediated silencing of ORAI3 in MDA-MB-468 breast cancer cells exposed to hypoxia 6.11
Effect of REST on cancer invasiveness in MCF-7 and MDA-MB-231 cells using RNA-sequencing (RNA-seq) analysis . 5.92
Gene expression and chromatin organization changes in lamin A/C haploinsufficient human induced pluripotent stem cell-derived cardiomyocytes 5.86
Gene expression and chromatin organization changes in lamin A/C haploinsufficient human induced pluripotent stem cell-derived cardiomyocytes [RNA-seq] 5.86
Mutation independent activation of the Notch pathway is associated with Lapatinib resistance in Her2+ breast cancer cell lines 5.67
Long non-coding RNA RP11-19E11.1 is an E2F1 target required for tumor cell proliferation and survival in basal breast cancer 5.66
RNA Expression Profile of Calcified Bicuspid, Tricuspid and Normal Human Aortic Valves by RNA Sequencing [TAV] 5.57
RNA isoform screens reveal the essentiality and tumor suppressor activity of ultraconserved poison exons 5.56
Silencing p300 in MCF7 cells to study expression and alternative splicing 5.54
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 1) 5.5
RNA sequencing for human induced pluripotent stem cell cardiomyocyte differentiation 5.4
Transcriptomic analysis of frontal fibrosing alopecia 5.39
Genome-wide expression change by SHARPIN knockdown in MCF-7 cells 5.15
The cytokine environment influence on human skin-derived T cells 5.03
RNA-seq Analysis of Castration-Resistant Prostate Cancer With Knock-down of E2F1 4.87
The effect of Abl kinases on non-small cell carcinoma global transcriptome 4.83
RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins 4.82
Patient-derived luminal breast cancer xenografts with progestins 4.82
Identification of expressed and conserved human non-coding RNAs 4.76
Effect of hyper-and hypoactivation of Notch signaling in IL-4-stimulate THP-1 4.6
Lipid degradation promotes prostate cancer cell survival 4.44
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance 4.35
Analysis of transcrptomes of Danon patient derived hiPSC-cardiomyocytes by RNA-deep Sequencing 4.26
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures [RNA-Seq] 4.17
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures 4.17
Next Generation Sequencing Facilitates Quantitative Analysis of Retinoblastoma Transcriptomes 4.17
Genome wide expression change by RNF168 knocking down in MCF-7 cells 4.09
BRG1 governs Glucocorticoid Receptor interactions with chromatin and pioneer factors across the genome 3.95
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L 3.89
Replicated transcriptome profiling of Normal and Cancerous Prostate Cells [RNA-Seq] 3.82
Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations 3.8
Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations [RNA-seq] 3.8
Targets of CDK12 on ZR-75-30 breast cancer cells (RNA-seq) 3.77
Gene expression profile of calcified and normal tricuspid aortic valves by RNA sequencing. 3.75
Regulartory effect of HNRNPL and LARP on RNA expression in LNCaP prostate cancer cells 3.73
HNRNPL and its RNA Targets in Prostate Cancer 3.73
ONECUT2 Drives Neuroendocrine Prostate Cancer Through Hypoxia Signaling 3.52
RNAseq analysis of ESRP regulated splicing events in prostate cancer 3.5
Supraphysiological Androgens Repress Prostate Cancer Growth and Induce DNA Damage Augmented by PARP Inhibition 3.46
MUC1-C Drives Lineage Plasticity in Progression to Neuroendocrine Prostate Cancer 3.45
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer 3.4
Impact of DNA MMR activity on antiviral gene expression in H441 cells infected with influenza A virus 3.39
Differential effects of estrogen receptor beta isoforms on glioblastoma progression 3.3
Analysis of human ES cell differentiation establishes that the dominant isoforms of the lncRNAs RMST and FIRRE are circular 3.28
Combinatorial Reprogramming of Estrogen Signaling by the Nuclear Receptor Family 3C 3.24
Transcriptome profiling of Normal and Cancerous Prostate Cells 3.2
Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 3.16
Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR- PCa cells 3.15
Control of prostate tumour growth by the long non-coding RNA GHSROS (LNCaP) 3.15
Human Induced Pluripotent Stem Cells Recapitulate Breast Cancer Patients’ Predilection to Doxorubicin-Induced Cardiotoxicity 3.13
Gene expression profile of regenerated CD8αα T cells and CD8αβ T cells from LMP2 T-iPSCs 3.02
CENPA-Bound Genes and Transcriptional Profiling of CENPA-Depleted Prostate Cancer Cells 3.02
Transcriptional Profiling of CENPA-Depleted Prostate Cancer Cell Lines 3.02
Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer 3.01
SUV420H2 knockdown in PANC-1 2.99
Arnica montana stimulates extracellular matrix gene expression in human macrophages differentiated to wound-healing phenotype. 2.94
Transcriptomic analysis of trametinib-resistant HCT116 colorectal carcinoma cells compared to the parental control cells 2.93
Transcriptomics analysis of gene expression in multiple human and mouse cells and tissues 2.9
A RUNX2-mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells 2.9
Arginine citrullination at the C-terminal domain controls RNA Polymerase II transcription 2.84
T47D RNA-seq and ChrRNA-seq data 2.84
Estrogen deprivation triggers and immunosuppressive phenotype in breast cancer cells 2.83
KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone 2.82
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer (RNA-seq) 2.8
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer 2.8
Transcriptome profiling of CXCR2+ neuroendocrine (NE) tumor cells purified from patients' fresh prostate adenocarcinoma 2.79
Prostate Cancer Cell RNA-Seq (PC3E and GS689.Li) 2.78
Overexpression of NFIB and YBX1 in MCF-7 cells 2.78
Gene expression profile in breast cancer cell lines using RNA sequencing 2.77
Bioinformatics analysis of transcriptome related to blood stasis syndrome in diabetes mellitus patients 2.72
Inhibition of ERG Activity in Patient Derived Prostate Cancer Xenografts using the Small Molecule Inhibitor YK-4-279 2.72
Genome-wide transcriptome analysis of NIPBL iPSC and commited cardiomyoctes 2.71
Genome wide transcript and miRNAanalysis of invitro and in-vivo generated human cardiac samples 2.67
Non-IG Aberrations of FOXP1 in B-Cell Malignancies Lead to an Aberrant Expression of N-Truncated Isoforms of FOXP1 2.61
Knockdown of FOXP1 promotes the development of lung adenocarcinoma 2.51
Exploring the gene expression profile upon FXR1 knockdown in H358 cells using RNA-seq 2.44
Transcriptomic Reprogramming of Prostate Cancer Cells Driven by Stroma-Derived SPINK1 2.42
RNA-seq analyses of human prostate cancer cells 2.36
RNA Expression Profile of Calcified Bicuspid, Tricuspid and Normal Human Aortic Valves by RNA Sequencing [BAV] 2.3
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 2.27
Determination of a comprehensive alternative splicing regulatory network and the combinatorial regulation by key factors during Epithelial-to-Mesenchymal Transition [RBM47 KD] 2.26
Identification of HOXB13 target genes responsive to BET inhibitors 2.2
RNA Sequencing of Human iPS derived Cardiomyocytes 2.18
RNA-seq analysis reveals endogenous aryl hydrocarbon receptor regulation is highly associated with eicosanoid synthesis and tumor necrosis factor activity in MCF-7 cancer cells 2.16
Increased Serine and One Carbon Pathway Metabolism by PKCl/i Deficiency Promotes Neuroendocrine Prostate Cancer [RNA-seq] 2.15
Increased Serine and One Carbon Pathway Metabolism by PKCl/i Deficiency Promotes Neuroendocrine Prostate Cancer 2.15
RNA-sequencing of tamoxifen-resistant and -sensitive breast cancer cell lines. 2.13
The Human Testis Cell Atlas via Single-cell RNA-seq (Healthy men scRNA-seq data set) 2.11
Regulation of cellular heterogeneity and rates of symmetric and asymmetric divisions in triple-negative breast cancer 2.11
Identification of the RB loss-induced transcriptome in prostate cancer [RNA] 2.09
Identification of the RB loss-induced transcriptome and E2F1 cistrome in prostate cancer 2.09
Patient Derived Xenograft for Delivery of Precision Medicine in Castrate Resistant Prostate Cancer 2.08
RNA-Seq Analysis of Anacardic Acid Treated MCF7 and MDA-MB-231 Breast Cancer Cell Lines 2.07
RB tumor suppressor promotes cancer immunity through downregulating PD-L1 expression 2.05
Analysis of human, chimpanzee, macaque and mouse tissue transcriptomes using Next Generation Sequencing 2.04
Estrogen receptor and mTOR signaling rewires cancer metabolism in obesity-associated breast cancer 2.01
G9a-Mediated Methylation of ERα Links the PHF20/MOF Histone Acetyltransferase Complex to Hormonal Gene Expression 2.0
Genome wide expression change in LCC2 and MCF-7 cells 1.94
Neurofibromin is an Estrogen Receptor alpha Transcriptional Co-repressor in Breast cancer 1.94
Electronic cigarettes 1.93
RNA-seq analysis of PRMT5-regulated genes in irradiated/non-irradiated LNCaP cells 1.92
Genome-wide maps in MCF-7 cells with six2 or CYP4Z1 3'UTR or CYP4Z2P 3'UTR overexpression or not 1.9
Disease Model of GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis [RNA-Seq] 1.9
Disease Model of GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis 1.9
RNA sequencing for lncRNA, miRNA and mRNA expression analysis in human laryngeal cancer 1.89
Discovery of cis-spliced chimeric RNAs between adjacent genes in human prostate cells 1.89
Identification of Atrial Fibrillation associated genes and functional non-coding variants 1.85
Forkhead domain mutations in FOXA1 drive prostate cancer cell progression 1.84
RNA-seq in LNCaP cell line overexpressing WT or mutant FOXA1 1.84
Genome-wide CRISPR-Cas9 screen identifies SLC1A3 as a key contributor to L-asparaginase Resistance in Solid tumors 1.84
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells 1.84
TALEN-based knockout of mir-141 and mir-200c in SK-BR-3 cells 1.76
Risk SNPs mediated promoter-enhancer switching promotes prostate cancer progression through lncRNA PCAT19 1.75
Risk SNPs mediated promoter-enhancer switching promotes prostate cancer progression through lncRNA PCAT19 (RNA-seq data sets) 1.75
Three-dimensional Oxabicycloheptene sulfonate targets the homologous recombination and repair programs through estrogen receptor α antagonism 1.73
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer 1.71
Cistromic re-programming by truncating GATA3 mutations promotes mesenchymal transformation in vitro, but not mammary tumour formation in mice [RNA-seq] 1.69
Cistromic re-programming by truncating GATA3 mutations promotes mesenchymal transformation in vitro, but not mammary tumour formation in mice 1.69
Genes directly regulated by NF-κB in human hepatocellular carcinoma HepG2 1.68
Genes directly regulated by NF-κB in human hepatocellular carcinoma HepG2 [RNA-seq] 1.68
Long non-coding RNA expression profile associated with malignant progression of oral submucous fibrosis 1.68
Transcriptome analysis of human lung epithelial cells 1.67
Non-coding and coding transcriptional profiles are significantly altered in pediatric Retinoblastoma tumors 1.66
LNCaP treated with iBET 1.66
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21 (RNA-Seq) 1.64
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21 1.64
ChIP-seq of ER and RUNX2 in MCF7 breast cancer cell lines 1.63
Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells 1.62
Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer 1.57
5hmC and gene expression data in breast cancer cell lines treated with an antioxidant 1.55
Conservative alteration of chromosomal expression pattern across human solid tumor types 1.54
PANCR, the PITX2 adjacent noncoding RNA, is specifically expressed in human left atria and regulates PITX2c expression 1.54
Paxillin regulates genomic networks in prostate cancer [C4-2] 1.53
Distinct Pathological Signatures in Human Cellular Models of Myotonic Dystrophy Subtypes 1.53
Global gene expression profiles of cardiomyocytes differentiated from human pluripotent stem cells (hiPSC-CMs) in 3D culture exposed to ethanol 1.52
Effect of selective glucocorticoid receptor modulation (SGRM) on gene expression in human prostate cancer cell lines 1.52
Genome-wide RNA-sequencing (RNA-seq) of benign and malignant prostate cell lines without and with androgen (R1881) stimulation. 1.5
Effects on gene expression of doxorubicin in human stem cells-derived cardiomyocytes 1.48
Identification of PRMT5-dependent genes in ESA+CD24lowCD44+ MCF7 cells 1.47
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 2) 1.46
Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer 1.46
A genomic study of the contribution of DNA methylation to regulatory evolution in primates 1.4
Expression profiling of MCF-7 cells with treatment of TCDD 1.4
Expression profiling of MCF-7 cells with 10nM treatment of TCDD 1.4
NAD+ Analog-sensitive PARPs Reveal a Role for PARP-1 in Transcription Elongation 1.39
Single-cell transcriptome of human epithelial cells reveals novel insights into early innate immune responses to influenza virus and viral antagonism 1.39
The Chromatin-Looping Factor ZNF143 Engages at Looping Promoters to Favor the Estrogen Response in Breast Cancer (RNA-seq) 1.38
The Chromatin-Looping Factor ZNF143 Engages at Looping Promoters to Favor the Estrogen Response in Breast Cancer 1.38
Identification of the O-GlcNAc-regulated alternative splicing events by performing RNA sequencing on HeLa cells with altered O-GlcNAc level. 1.38
Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer 1.38
Transcriptional Targeting Of Oncogene Addiction In Medullary Thyroid Cancer [RNA-Seq] 1.38
Fusion discovery in breast cancer cell line 1.37
Effect of PBK knockdown on C4-2 cell transcriptome 1.36
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. 1.34
Sequencing of ponatinib-resistant LC-2/ad derivatives (PR1 and PR2) and parental LC-2/ad cells 1.34
RNA-seq and ChIP-seq analysis of BMI1 or RING1B-silenced prostate cancer cells C4-2 1.33
Identification of Tissue-Specific Protein-Coding and Noncoding Transcripts across 14 Human Tissues Using RNA-seq 1.31
Energy Metabolism during Anchorage-Independence 1.31
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade 1.28
Genome-wide Analysis of Chromatin Interactions in Human Cells 1.27
Investigate A2M treatment on human prostate cancer xenograft in mice 1.26
Investigate A2M treatment on human prostate cancer and mouse liver 1.26
Expression profiling and occupancy after knockdown or over-expression of HFN1A or HNF4G in prostate cancer cells 1.25
Identification of ZEB1-regulated gene expression changes in HCC827 human lung adenocarcinoma cells 1.25
RNA-Seq with and without RNase treatment in PCa cell lines 1.24
RNA Seq data: A375, A375R, A375DR vorinostat treated, and biopy samples from patients pre- and post- treated with Vorinostat 1.24
An acquired vulnerability of drug resistant melanoma with therapeutic potential 1.24
A prostate cancer chromatin interaction map 1.23
Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with Eralpha 1.21
TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes 1.2
Essential Roles of SETD7 as Transcriptional Activator and Co-regulator of H3K36me in Cardiac Lineage Commitment 1.2
RNA-seq of cancer cell lines treated with T-025 1.19
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor 1.18
Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation (Human_RWPE1_RNA-Seq) 1.18
Identification of an NKX3.1-G9a-UTY regulatory network that controls prostate differentiation 1.18
Oxaliplatin resistance is enhanced by saracatinib via upregulation of ABCG1 and Wnt/β-catenin signaling in hepatocellular carcinoma 1.18
ROR-γ drives androgen-receptor expression and represents a therapeutic target in castration-resistant prostate cancer 1.15
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer 1.15
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq) 1.15
Derivation of ventrical and atrial cardiomyocytes and maturation using biowires 1.14
The global transcriptome analysis in the time course of hESC-derived cardiac differentiation 1.13
The effect of REST and its alternatively spliced transcript, REST-003, on breast cancer invasiveness 1.12
A non-canonical role of YAP/TEAD is required for activation of estrogen-regulated enhancers in breast cancer [RNA-seq] 1.11
A non-canonical role of YAP/TEAD is required for activation of estrogen-regulated enhancers in breast cancer 1.11
Next Generation Sequencing Facilitates Quantitative Analysis of miR-29b-1 and miR-29a targets in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells 1.09
Transciptomic profiling of human fetal lung samples 1.08
TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells 1.08
TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells [RNA-seq] 1.08
Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds 1.07
Proteotranscriptomic profiling of potential E6AP targets in prostate cancer cells 1.04
Next-generation sequencing analysis of transcriptom in gemcitabine resistant pancreatic cancer cells 1.03
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-seq C-terminal mutant] 1.02
LIN28A modulates splicing and gene expression programs in breast cancer cells 0.98
LIN28A modulates splicing and gene expression programs in breast cancer cells [RNA-Seq] 0.98
Characterization of sperm lncRNA and its differently expression in the sperm of asthenozoospermic patients 0.98
Characterization of parental and rociletinib-resistant derived H1975 cell lines 0.97
Assembly of methylated LSD1 and CHD1 drives AR-dependent transcription and translocation 0.95
Assembly of methylated LSD1 and CHD1 drives AR-dependent transcription and translocation [RNA-Seq] 0.95
Transcriptome-wide modulation of splicing by the exon junction complex 0.95
RNA-seq of YB5 and MCF7 treated with different doses of decitabine 0.95
RNA-seq data corresponding to: AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells 0.94
CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops 0.94
Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone 0.94
Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone [IMR90_MCF7_RNA-Seq] 0.94
Effect of Polybrominated diphenyl ethers (PBDEs) on gene expression of MCF7 cells 0.93
Identification of global XBP1s target gene expression in human prostate cancer cells 0.93
The landscape of alternative splicing in aggressive prostate cancers 0.92
Differential RNA-seq analysis comparing APC-defective and APC-restored SW480 colorectal cancer cells 0.91
RNA-Seq profiling of iPSC-derived ventricular and atrial cardiomyocytes 0.89
Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer 0.89
MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance 0.89
MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance (RNA-Seq) 0.89
A common cell state in Triple Negative Breast Cancers represents a druggable vulnerability 0.87
RNA-sequencing experiment: Treatment of MCF-7 breast cancer cells with the novel small molecule ZNA 0.87
RNA-Seq analysis of prostate cancer cell line LNCaP treated with vehicle, androgen, androgen and IMTPPE, androgen and JJ-(+)-450, androgen and JJ-(-)450, androgen and enzalutamide 0.85
DDX54 regulates transcriptome dynamics during DNA damage response [RNA-seq2] 0.84
mRNAseq of Huntington's disease and control patient iPSC-derived neural cells 0.84
Transcriptomic and Epigenomic analysis of Huntington's disease and control patient iPSC-derived neural cells 0.84
Comparing oestrogen-responsive genes in endometrial and breast cancer cell lines 0.84
Gene expression analysis of C4-2 cells treated with ACLY inhibitor and Enzalutamide 0.83
Bromodomain protein BRD4 is required for estrogen receptor-dependent transcription and enhancer activation [RNA-Seq] 0.82
Bromodomain protein BRD4 is required for estrogen receptor-dependent transcription and enhancer activation 0.82
mRNA sequencing analysis of cultured human primary airway epithelial cells upon exposure to PMN exosomes 0.8
RNA-sequencing and MeDIP-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells 0.79
RNA-sequencing of shSRC-1 and shNT tamoxifen treated LY2 cells 0.79
The Human Testis Cell Atlas via Single-cell RNA-seq 0.77
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression 0.77
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression [RNA-seq] 0.77
An integrative network biology analysis identifies miR-508-3p as the determinant and a prognosis biomarker of the mesenchymal subtype ovarian cancer 0.77
Transcriptomics analysis of gene expression in normal and YTHDC1, SRSF1, SRSF3, SRSF7, SRSF9 or SRSF10 deficient human HeLa cells 0.76
Contribution of SRF and Nkx2-5 to androgen-dependent gene expression in prostate cancer 0.76
Genome-wide expression profiling of an in vitro model for studying esophageal epithelial differentiation 0.76
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle [RNA-seq] 0.76
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle 0.76
Transcriptomic analysis of acute mitochondrial pyruvate carrier inhibition using UK5099 in ABL prostate cancer cells 0.74
Polycomb complexes associate with enhancers to promote oncogenic transcriptional programs in cancer 0.74
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells 0.73
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells [RNA-seq] 0.73
MCF-7 as a model for functional analysis of breast cancer risk variants 0.73
Transcriptome sequencing of differentially expressed genes in acne inversa (AI) patients with NCSTN mutation and healthy individuals 0.71
Transcriptome sequencing of differentially expressed genes in mouse and human skin with and without NCSTN mutation 0.71
RNA-Seq of human induced pluripotent stem cell-derived cardiomyocytes from a cardiomyopathy patient and familial control 0.7
RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer 0.7
RNA-seq analysis of SLIRP knockdown with 1nM DHT in LNCaP cells 0.7
Dtx3L and Androgen Signaling in Prostate Cancer 0.69
RNA sequencing of prostate cancers reveal insights on the prognostic significance of visibility on multi-parametric MRI 0.66
Oncogenic Notch promotes long-range regulatory interactions within hyperconnected 3D cliques 0.66
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator [RNA-seq] 0.66
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator 0.66
Single Cell RNA-sequencing of cell types isolated by FACS from normal human prostates 0.66
Intrinsic histone acetyltransferase activity of BRD4 is responsible for nucleosome eviction and transcriptional activation 0.65
BASP1 modifies the Tamoxifen response 0.65
Integrator complex regulates NELF-mediated RNA Polymerase II pause/release and processivity at coding genes [RNA-seq] 0.64
Integrator complex regulates NELF-mediated RNA Polymerase II pause/release and processivity at coding genes. 0.64
ARID1A is a critical regulator of luminal identity and therapeutic response in oestrogen receptor-positive breast cancer (RNA-Seq) 0.64
Gene expression by high-throughput sequencing of T47D-MTVL human breast cancer cells upon H1.4 knock-down and multiple H1 variants 0.63
Microvesicle-mediated delivery of miR-1343: impact on markers of fibrosis 0.62
Distinct changes in transcriptional profiles and epigenetic patterns mediated by EZH2 inhibitors in sensitive and insensitive prostate cancer cells 0.61
EZH2 inhibitor-mediated transcriptional profiling in prostate cancer cells [RNA-seq] 0.61
Suppression of NAF-1 in Breast Cancer Cells Reduces their Tumorigenicity by Interfering with Cellular Iron Distribution and Metabolism and Ensuing ROS Formation and Apoptosis 0.61
Oncogenic Notch promotes long-range regulatory interactions within hyperconnected 3D cliques [HCC1599_RNA-seq] 0.61
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer [RNA-seq] 0.6
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer 0.6
The E3 ubiquitin ligase HectD1 suppresses EMT and metastasis by targeting the +TIP protein ACF7 for degradation 0.6
ZRANB2 and SYF2 mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin 0.59
Transcriptomic Reprogramming of Prostate Cancer Cells Driven by Stroma-Derived AREG 0.59
A bioinformatics approach reveals novel mechanisms of the OVOL transcription factors in the regulation of epithelial-mesenchymal cell programming and cancer progression. 0.59
Gene expression analysis of ER+ and ER- breast cancer cell lines with acquired resistance to palbociclib 0.59
Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming 0.58
Identification of a LIF-responsive replication-competent human β cell 0.57
The IMiDs, through loss of Ikaros and Aiolos, primes myeloma cells for daratumumab mediated killing by upregulation of CD38 0.57
A Druggable TCF4- and BRD4-dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm (RNA-Seq) 0.57
NET-CAGE Characterizes the Dynamics and Topology of Human Transcribed Cis-regulatory Elements 0.56
Transcriptome of invasive mucinous adnocarcinoma of the lung and adjacent normal lung tissues from 6 patients based on RNA-seq method 0.55
Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer 0.54
Somatic cell fusions reveal extensive heterogeneity in basal-like breast cancer [RNA-Seq] 0.54
Waterpipe Smoking Induces Epigenetic Changes in the Small Airway Epithelium [RNA-Seq] 0.54
Waterpipe Smoking Induces Epigenetic Changes in the Small Airway Epithelium 0.54
WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export with transcription 0.53
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma 0.53
Messenger RNA expression after silencing or inhibition of MEN1in MCF-7 breast cancer cells 0.52
H3K27Ac in MCF7 Y537S ER mutant cells and RNAseq with and without treatment with THZ1 0.52
TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation 0.51
Whole transcriptome splicing analysis in isogenic lung epithelial and adenocarcinoma cell lines with or without a recurrent splicing factor mutation, U2AF1 (S34F) 0.51
Tamoxifen Resistance in Breast Cancer is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis 0.51
Disrupted prenatal RNA processing and myogenesis in congenital myotonic dystrophy 0.5
Characterizing smoking-induced transcriptional heterogeneity in the human bronchial epithelium at single-cell resolution 0.49
EWSR1 influences alternative splicing through direct and indirect mechanisms 0.49
RNA sequencing of lncRNAs knockdown in human pancreatic cancer cell lines 0.49
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression [RNA-Seq] 0.49
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression 0.49
Effect of PDZ domain binding Kinase inhibition using TOPK-32 (called PBKi) on C4-2 cell transcriptome 0.48
Integrative Analysis of Tamoxifen-resistant Cell Line Models Based on Sequencing Genomes, Transcriptomes and Epigenomes [seq] 0.48
Integrative Analysis of Tamoxifen-resistant Cell Line Models Based on Sequencing Genomes, Transcriptomes and Epigenomes 0.48
Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer 0.48
High-depth RNA sequencing of isogenic wild-type, PIK3CA-WT/H1047R and PIK3CA-H1047R/H1047R human iPSCs 0.47
Global Bidirectional Transcription of the Epstein-Barr Virus Genome During Reactivation 0.47
Proliferation-correlated expression 0.47
LED, a long non-coding RNA activator of enhancer RNAs, is hypermethylated in human cancers 0.46
Tracing Enhancer Networks using Epigenetic Traits (TENET) 0.45
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma [RNA-Seq; normal samples] 0.45
Global modulation of signaling pathways by SARM RAD140 in AR/ER+ breast cancer xenografts 0.45
Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy 0.44
Gene expression profiling of patient's DCIS-IDC tandem lesions by RNA sequencing analysis 0.44
Identification of transcription start sites for human A549 cell line using ReCappable-seq 0.44
Reprogramming of Tumor-infiltrating Immune Cells in Early Stage of NSCLC 0.44
Effect of drugs on transcriptomic profiles 0.44
Evidence for HOXC6 as a potential molecular marker for non-small cell lung cancer 0.44
Active translatome profiling with RiboLace in MCF7 cells 0.43
KDM1A confers invasive and metastatic attributes in lung adenocarcinoma by modulating a non-canonical Integrin ß3-KRAS signaling pathway 0.43
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity 0.42
RNA sequencing Facilitates Quantitative Analysis of luminal breast cancer cells and basal breast cancer cells Transcriptomes 0.41
Genome-wide modelling of transcription kinetics reveals patterns of RNA processing delays 0.41
Distinct structural classes of activating FOXA1 alterations in prostate cancer progression 0.41
Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [RNA-Seq] 0.41
Retinoic Acid Induced Transcriptional Repressor HIC1 is Required for Suppressive Function of Human Induced Regulatory T cells [RNA-Seq 1] 0.4
Comparison of expression profiles of APP-depleted prostate cancer cells (LNCaP) 0.4
Transcriptome analysis of PC9 cells with gefitinib or/and hypoxia treatment and comparison with gefitinib resistant PC9 cells and ALDH positive PC9 cells 0.4
ERK signaling regulates opposing functions of JUN family transcription factors in prostate cancer cell migration 0.39
Gene expression profiling study by RNA-seq for identifying genes associated with epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 0.38
Epithelial-mesenchymal transition and acquired resistance to ALK inhibitors 0.38
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines [RNA-seq] 0.37
Mapping of DHT-responsive or -independent AR-binding sites induced by activated Src in prostate cancer cell lines 0.37
RNAseq of cell lines with knocked in ESR1 mutations 0.37
mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer 0.36
DDX54 regulates transcriptome dynamics during DNA damage response [4SU-seq] 0.36
CDK12 regulates alternative last exon mRNA splicing and promotes invasion of a breast cancer cell line 0.35
Dynamic gene regulatory networks of human myeloid differentiation [RNA-seq_siRNA] 0.35
Effects of Polybrominated Diphenyl Ether (PBDE) Mixture on estrogen receptor positive (ER+) patient-derived tumor xenograft (PDX) model 0.35
RNA-seq analysis of breast cancer 0.35
RNA-seq analysis and shRNA screen of breast cancer 0.35
Effect of SF3B1 suppression in cancer cells with different SF3B1 copy-number levels 0.34
Oligogenic inheritance of congenital heart disease involving a NKX2-5 modifier [human] 0.34
Oligogenic inheritance of congenital heart disease involving a NKX2-5 modifier 0.34
Human Treg NaCl stimulation 0.34
Transcriptomic characterization of a human in vitro model of arrhythmogenic cardiomyopathy under topological and mechanical stimuli 0.33
Canonical and non-canonical regulatory roles of androgen receptor variant 7 in prostate cancer 0.33
Gene expression and genome-wide location analysis of breast cancer cell-lines 0.32
Gene expression analysis of breast cancer cell-lines 0.32
Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection 0.31
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair 0.31
The transcriptome effect of overexpressing EZH2 in MCF7 0.3
Short-term effect of Boost versus Radical doses of Intraoperative electron Radiotherapy in breast cancer tumor bed using high-throughput approaches 0.29
mRNA-sequencing of breast cancer subtypes and normal tissue 0.29
Dissecting cell composition and cell-cell interaction network of human disease heart tissue by single-cell sequencing 0.28
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence 0.28
T47D xenografts treated with various combinations of ER- and PR-targeting therapies 0.28
SREBP1 drives Keratin 80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer 0.28
Effects of plasticizers (bisphenol A, bisphenol AF) and an herbicide in MCF7 human breast cancer cells 0.27
IKZF1 as a Master Regulator of Immune Infiltrate Recruitment in Solid Tumors 0.27
ENCODE Cold Spring Harbor Labs Long RNA-seq 0.27
Lung adenocarcinoma metastasis is suppressed by the alveolar lineage transcription factors GATA6 and HOPX. 0.25
CD13 and ROR2 permit isolation of highly enriched cardiac mesoderm from differentiating human embryonic stem cells 0.25
Isolation of highly enriched cardiac mesoderm from differentiating human embryonic stem cells 0.25
Preclinical model of obesity and ER-positive breast cancer 0.24
RNA-Seq analysis of cSCC cells followed by siRNA-induced gene knockdown of C1s. 0.23
Low-dose decitabine priming endows CAR T cells with enhanced and persistent anti-tumor potential by epigenetic reprogramming 0.22
Whole Transcriptomic Sequencing of Metastatic Castration Resistant Prostate Cancer Samples 0.22
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition [RNA-seq] 0.21
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition 0.21
RNA-seq profiling identifies Androgen Receptor-regulated genes in prostate cancer cells 0.21
Androgen Receptor-regulated genes in prostate cancer cells 0.21
Modeling Trilateral Retinoblastoma using Human Embryonic Stem Cells 0.2
Nudt3 is a mRNA Decapping Enzyme That Modulates Cell Migration 0.2
SILAC identifies LAD1 as an oncogenic filamin binder regulating actin dynamics in response to EGF and marking aggressive breast tumors 0.19
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression 0.18
Osmostress induced changes of chromatin architecture and transcription in mammalian cells 0.18
Osmostress induced changes of chromatin architecture and transcription in mammalian cells [RNA-Seq, HiC] 0.18
The Wnt/β-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth 0.17
RNA-Seq Analysis in purified iPS cell-derived neuronal samples 0.16
Interaction between mitoNEET and NAF-1 in cancer cells 0.16
Transcriptomic analysis of inter- and intra-patient variation in human iPSC cardiomyocytes: Platform for precision medicine to predict drug toxicity 0.16
Role of SUMOylation in differential ERα transcriptional repression by SERMs and pure antiestrogens in breast cancer cells 0.16
Dilated cardiomyopathy vs Myocarditis 0.16
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma 0.14
Single Cell RNASeq profiling of stromal vascular fraction from Subcutaneous and visceral adipose tissue 0.14
RNAseq of Breast cancer PDX samples 0.14
Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy 0.14
Modeling genome-wide transcriptional cis-regulation in n LNCaP-abl cell line after siRNA knock down of a series of gene factors [RNA-seq] 0.14
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC derived cardiomyocytes. 0.13
Evaluation of the effectiveness of semen collection and sperm purification methods for spermatozoa transcript profiling 0.13
Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells 0.13
Combined MEKi (GDC-0973) and WNT (G007-LK) treatment in APC and KRAS mutant HCT-15 cell line 0.11
Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation 0.11
Loss of Function Mutations in ETS2 Repressor Factor (ERF) Reveal a Balance Between Positive and Negative ETS Factors Controlling Prostate Oncogenesis [22PC RNA-seq] 0.1
Engineering Patient-Specific Tissue Implants 0.1
Activating Transcription Factor 4 modulated TGFb-induced aggresiveness in triple negative breast cancer vis SMAD2/3/4 and mTORC2 signaling 0.1
eRNA: A graphic user interface-based tool for RNA sequencing data analysis [mRNA-Seq] 0.1
eRNA: A graphic user interface-based tool for RNA sequencing data analysis 0.1
Expression changes in MAPKi resistant M229 melanoma lines co-cultured with PD-1 overexpressing HEK293T cells [CellLine.FPKM.batch5] 0.09
PTHrP overexpression in MCF7 cells 0.09
Gene expression of collecting duct carcinoma of the kidney 0.08
Glucose inhibits cardiac maturation through nucleotide biosynthesis 0.08
Illumina HiSeq Sequencing on Breast cancer PDX samples 0.08
ATXN7L3 And ENY2 Coordinate Activity Of Multiple H2B Deubiquitinases Important For Cellular Proliferation And Tumor Growth 0.08
ATXN7L3 And ENY2 Coordinate Activity Of Multiple H2B Deubiquitinases Important For Cellular Proliferation And Tumor Growth [RNA-Seq] 0.08
CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer 0.08
Muscle transcriptome analysis following Total Knee Arthroplasty with Tourniquet 0.08
Targets of ROR2 overexpression in MCF-7 cells revealed a differentially regulated module of non-canonical WNT signaling pathway 0.07
Screening in Human Cardiac Organoids Identifies a Requirement for the Mevalonate Pathway in Cardiomyocyte Proliferation 0.07
rG4-seq reveals widespread formation of G-quadruplex structures in the human transcriptome 0.07
RNA-seq of SCLC PDX models treated with EP 0.06
Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia 0.05
Genome-wide effect of inhibition of glutamine transporter ASCT2 in PC-3 cells by BenSer or GPNA 0.05
Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001 0.05
Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny 0.04
Genome-wide analysis of the Integrator complex 0.04
Genome-wide analysis of the Integrator complex (HTS) 0.04
FOXA1 Chromatin Binding is Regulated by LSD1-Mediated Demethylation 0.04
RNA-Seq with DHT induction and/or GSK treatment at 24, 48 hrs and 2 weeks 0.04
Transcriptomic Analysis of Endothelial Cells from Fibrovascular Membranes in Proliferative Diabetic Retinopathy 0.04
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-FU-Mediated Cytotoxicity in Multiple Human Cancer Types 0.04
FOXP3 protects conventional human T cells from premature restimulation-induced cell death 0.03
Single cell RNA-seq resolves lineage-specific activation dynamics of human blood and tissue T cells 0.03
Club cells surviving influenza A virus infection induce temporary non-specific anti-viral immunity 0.03
Paxillin regulates genomic networks in prostate cancer [LNCaP] 0.02
A single cell reference map for human blood and tissue T cell activation 0.01
Characterizing the Chemoresistant Ovarian Cancer Population using the Heterogeneous PDX 0.01
RNAseq analysis of ruxolitinib treated breast cancers 0.01
Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue 0.01


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation